EMA addresses considerations for single-arm trials A new reflection paper from the European Medicines Agency (EMA) offers some suggestions to sponsors on how to design single-arm trials (SATs) and ...
The US Food and Drug Administration (FDA) aimed to address some of the criticisms of its accelerated approval program with new draft guidance that expresses a preference for using randomized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results